AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims

3D rendering of a blue virus particle surrounded by yellow antibodies, illustrating an immune response at the microscopic level Featured image for article: AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims

The Delhi High Court has dismissed AbbVie’s appeal regarding the refusal of their patent application for an anti-cMet antibody-drug conjugate. The court found the proposed amendments exceeded permissible scope under the Indian Patents Act.

Read more about AbbVie’s Patent Refusal Upheld over Impermissible Shift from Treatment to Product Claims

Method of producing ‘protein enriched blood serum’ is not a method of treatment under Section 3(i), says the Delhi High Court

The Delhi High Court ruled that a method of producing protein enriched blood serum is not a method of treatment under Section 3(i) of the Patents Act. The Court set aside the refusal and directed the Patent Office to reconsider the application after a fresh hearing.

Read more about Method of producing ‘protein enriched blood serum’ is not a method of treatment under Section 3(i), says the Delhi High Court